WO2020146541A3 - Traceless linkers and protein-conjugates thereof - Google Patents

Traceless linkers and protein-conjugates thereof Download PDF

Info

Publication number
WO2020146541A3
WO2020146541A3 PCT/US2020/012798 US2020012798W WO2020146541A3 WO 2020146541 A3 WO2020146541 A3 WO 2020146541A3 US 2020012798 W US2020012798 W US 2020012798W WO 2020146541 A3 WO2020146541 A3 WO 2020146541A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
protein
compounds
traceless
traceless linkers
Prior art date
Application number
PCT/US2020/012798
Other languages
French (fr)
Other versions
WO2020146541A2 (en
Inventor
Amy Han
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/012786 external-priority patent/WO2019136487A2/en
Priority to CN202080019317.3A priority Critical patent/CN113905767A/en
Priority to MX2021008114A priority patent/MX2021008114A/en
Priority to EP20702563.6A priority patent/EP3908323A2/en
Priority to MA53772A priority patent/MA53772B1/en
Priority to CA3125998A priority patent/CA3125998A1/en
Priority to US17/612,204 priority patent/US20230119539A1/en
Priority to KR1020217024347A priority patent/KR20210114008A/en
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Priority to EA202191914A priority patent/EA202191914A1/en
Priority to JP2021539640A priority patent/JP2022517767A/en
Priority to BR112021013464-6A priority patent/BR112021013464A2/en
Priority to MA59295A priority patent/MA59295A1/en
Priority to AU2020205662A priority patent/AU2020205662A1/en
Priority to SG11202107212QA priority patent/SG11202107212QA/en
Publication of WO2020146541A2 publication Critical patent/WO2020146541A2/en
Publication of WO2020146541A3 publication Critical patent/WO2020146541A3/en
Priority to IL284673A priority patent/IL284673A/en
Priority to CONC2021/0010315A priority patent/CO2021010315A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Abstract

Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management of the symptoms thereof, associated with inflammatory diseases and autoimmune disorders further associated with the glucocorticoid receptor, glucocorticoid binding, and/or glucocorticoid receptor signalling, including administration of the compounds or payloads via traceless linker-payloads, and protein conjugates thereof.
PCT/US2020/012798 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof WO2020146541A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EA202191914A EA202191914A1 (en) 2019-11-19 2020-01-08 Traceless Linkers and Their Protein-Conjugates
JP2021539640A JP2022517767A (en) 2019-01-08 2020-01-08 Traceless linker and its protein-conjugate
MX2021008114A MX2021008114A (en) 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof.
BR112021013464-6A BR112021013464A2 (en) 2019-01-08 2020-01-08 TRACELESS BINDERS AND PROTEIN CONJUGATES THEREOF
CA3125998A CA3125998A1 (en) 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof
US17/612,204 US20230119539A1 (en) 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof
KR1020217024347A KR20210114008A (en) 2019-01-08 2020-01-08 Immaculate linkers and protein-conjugates thereof
CN202080019317.3A CN113905767A (en) 2019-01-08 2020-01-08 Traceless linkers and protein conjugates thereof
SG11202107212QA SG11202107212QA (en) 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof
EP20702563.6A EP3908323A2 (en) 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof
MA53772A MA53772B1 (en) 2019-01-08 2020-01-08 TRACELESS LINKERS AND RELATED PROTEIN CONJUGATES
MA59295A MA59295A1 (en) 2019-01-08 2020-01-08 TRACELESS LINKERS AND RELATED PROTEIN CONJUGATES
AU2020205662A AU2020205662A1 (en) 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof
IL284673A IL284673A (en) 2019-01-08 2021-07-07 Traceless linkers and protein-conjugates thereof
CONC2021/0010315A CO2021010315A2 (en) 2019-01-08 2021-08-04 Traceless linkers and protein conjugates thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
PCT/US2019/012786 WO2019136487A2 (en) 2018-01-08 2019-01-08 Steroids and antibody-conjugates thereof
US16/243,020 US20190209702A1 (en) 2018-01-08 2019-01-08 Steroids and antibody-conjugates thereof
US16/243,020 2019-01-08
USPCT/US2019/012786 2019-01-08
US201962872229P 2019-07-09 2019-07-09
US62/872,229 2019-07-09
US201962937721P 2019-11-19 2019-11-19
US62/937,721 2019-11-19

Publications (2)

Publication Number Publication Date
WO2020146541A2 WO2020146541A2 (en) 2020-07-16
WO2020146541A3 true WO2020146541A3 (en) 2020-08-13

Family

ID=71521936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/012798 WO2020146541A2 (en) 2019-01-08 2020-01-08 Traceless linkers and protein-conjugates thereof

Country Status (14)

Country Link
EP (1) EP3908323A2 (en)
JP (1) JP2022517767A (en)
KR (1) KR20210114008A (en)
CN (1) CN113905767A (en)
AU (1) AU2020205662A1 (en)
BR (1) BR112021013464A2 (en)
CA (1) CA3125998A1 (en)
CL (1) CL2021001790A1 (en)
CO (1) CO2021010315A2 (en)
IL (1) IL284673A (en)
MA (2) MA59295A1 (en)
MX (1) MX2021008114A (en)
SG (1) SG11202107212QA (en)
WO (1) WO2020146541A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266353B2 (en) 2016-11-08 2024-03-01 Regeneron Pharma Steroids and protein-conjugates thereof
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023079362A1 (en) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Processable compositions and use for the same
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
TW202340252A (en) * 2022-01-29 2023-10-16 大陸商上海盛迪醫藥有限公司 Drug conjugates of glucocorticoids

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155998A1 (en) * 2014-04-10 2015-10-15 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
WO2017210471A1 (en) * 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US20180334426A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceutical, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
WO2018213077A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
CN108853514A (en) * 2017-08-18 2018-11-23 四川百利药业有限责任公司 There are two types of the antibody drug conjugates of different pharmaceutical for tool
CN109106951A (en) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 A kind of camptothecine-antibody coupling matter

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AR048098A1 (en) 2004-03-15 2006-03-29 Wyeth Corp CALIQUEAMYCIN CONJUGATES
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
WO2008153744A2 (en) 2007-05-23 2008-12-18 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
KR101000067B1 (en) 2008-12-30 2010-12-10 엘지전자 주식회사 Laser Firing Apparatus For High Efficiency Sollar Cell And Fabrication Method For High Efficiency Sollar Cell
PE20130342A1 (en) 2010-04-15 2013-04-20 Spirogen Sarl PIRROLOBENZODIACEPINES AND CONJUGATES OF THE SAME
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EP3170821B1 (en) 2011-05-27 2021-09-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
MX341523B (en) 2011-10-14 2016-08-24 Medimmune Ltd Pyrrolobenzodiazepines.
JP6393617B2 (en) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド Pyrrolobenzodiazepine and target conjugates
EA029046B1 (en) 2011-10-14 2018-02-28 Медимьюн Лимитед Pyrrolobenzodiazepines and intermediates for the preparation thereof, synthesis methods thereof
EP2753178B1 (en) 2011-10-14 2017-12-06 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CN110201186A (en) 2012-10-23 2019-09-06 西纳福克斯股份有限公司 Modified antibody, antibody-conjugate and preparation method thereof
AU2014283185B2 (en) * 2013-06-21 2019-05-02 Innate Pharma Enzymatic conjugation of polypeptides
TWI641620B (en) 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
MX2019003325A (en) 2016-09-23 2019-08-05 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof.
MX2020006994A (en) * 2018-01-08 2020-11-06 Regeneron Pharma Steroids and antibody-conjugates thereof.
EP3764830B1 (en) 2018-05-08 2021-07-21 Nike Innovate C.V. Bonding to polyolefin plates and articles of footwear formed therefrom
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155998A1 (en) * 2014-04-10 2015-10-15 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
WO2017210471A1 (en) * 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US20180334426A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceutical, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
WO2018213077A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
CN108853514A (en) * 2017-08-18 2018-11-23 四川百利药业有限责任公司 There are two types of the antibody drug conjugates of different pharmaceutical for tool
CN109106951A (en) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 A kind of camptothecine-antibody coupling matter

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAJAJ S ET AL: "Topochemical model for prediction of anti-HIV activity of HEPT analogs", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 2, 17 January 2005 (2005-01-17), pages 467 - 469, XP027800977, ISSN: 0960-894X, [retrieved on 20050117] *
CHO ET AL: "The first preparation of alpha-functionalized benzylamine", TETRAHEDRON LETTERS, vol. 40, no. 47, 19 November 1999 (1999-11-19), pages 8215 - 8217, XP005024955, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(99)01713-X *
FRANZ EFFENBERGER ET AL: "Trifluormethansulfonate von [alpha]-Hydroxycarbonsäureestern - Edukte zur racemisierungsfreien Synthese N-substituierter [alpha]-Aminosäuren", ANGEWANDTE CHEMIE, vol. 95, no. 1, 1 January 1983 (1983-01-01), pages 50 - 50, XP055685197, ISSN: 0044-8249, DOI: 10.1002/ange.19830950111 *
JEFFREY C. KERN ET AL: "Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs", BIOCONJUGATE CHEMISTRY, vol. 27, no. 9, 28 July 2016 (2016-07-28), pages 2081 - 2088, XP055557206, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.6b00337 *
PIA SVENDSEN ET AL: "Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOP, vol. 4, March 2017 (2017-03-01), pages 50 - 61, XP055578466, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2016.11.004 *
SAMANT ET AL: "Synthesis of 3-hydroxypyrid-2-ones from furfural for treatment against iron overload and iron deficiency", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 9, 1 September 2008 (2008-09-01), pages 1978 - 1982, XP025404797, ISSN: 0223-5234, [retrieved on 20071128], DOI: 10.1016/J.EJMECH.2007.11.013 *
SIMONE JEGER: "Site-specific conjugation of tumour-targeting, antibodies using transglutaminase", 2009, ETH Zürich, CH, XP055208841, Retrieved from the Internet <URL:http://dx.doi.org/10.3929/ethz-a-005963273> DOI: 10.3929/ethz-a-005963273 *
TUMEY L NATHAN ET AL: "ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 17, no. 32, 2017, pages 3444 - 3462, XP009517545, ISSN: 1568-0266, DOI: 10.2174/1568026618666180118154017 *

Also Published As

Publication number Publication date
JP2022517767A (en) 2022-03-10
WO2020146541A2 (en) 2020-07-16
EP3908323A2 (en) 2021-11-17
MA53772B1 (en) 2023-08-31
MA53772A1 (en) 2022-10-31
KR20210114008A (en) 2021-09-17
SG11202107212QA (en) 2021-07-29
CN113905767A (en) 2022-01-07
CO2021010315A2 (en) 2021-08-19
MA59295A1 (en) 2023-07-31
IL284673A (en) 2021-08-31
BR112021013464A2 (en) 2021-09-21
CL2021001790A1 (en) 2022-07-01
CA3125998A1 (en) 2020-07-16
AU2020205662A1 (en) 2021-07-22
MX2021008114A (en) 2021-08-05

Similar Documents

Publication Publication Date Title
WO2020146541A3 (en) Traceless linkers and protein-conjugates thereof
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
BRPI0514259A (en) binding domain fusion protein
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2021012205A (en) Heavy chain antibodies binding to psma.
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3838298A3 (en) Psma binding ligand-linker conjugates and methods for using
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
TW200626132A (en) Topical nepafenac formulations
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2022009390A (en) IL-7Rαγc BINDING COMPOUNDS.
WO2020057540A8 (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
PH12021551153A1 (en) Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
WO2019028182A3 (en) Cancer treatment using antibodies that bind human cd134 (ox40) receptor
MX2023000677A (en) Estrogen receptor-modulating compounds.
WO2019222449A8 (en) Protein binding nkg2d, cd16 and a fibroblast activation protein
WO2019234694A3 (en) Therapeutic methods using antibody drug conjugates (adcs)
MX2023008330A (en) Compositions and methods for the treatment of metabolic and liver disorders.
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
MX2023005693A (en) Heavy chain antibodies binding to folate receptor alpha.
WO2018175740A8 (en) Anti-tmeff1 antibodies and antibody drug conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20702563

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021539640

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3125998

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021013464

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020205662

Country of ref document: AU

Date of ref document: 20200108

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217024347

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020702563

Country of ref document: EP

Effective date: 20210809

ENP Entry into the national phase

Ref document number: 112021013464

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210707